Abstract:OBJECTIVE:Hepatic stellate cells (HSCs) transdifferentiation and subsequent inflammation are important pathological processes involved in the formation of cirrhotic portal hypertension. This study characterizes the pathogenetic mechanisms leading to cholestatic liver fibrosis and portal hypertension, and focuses on mammalian target of rapamycin (mTOR) pathway as a potential modulator in the early phase of cirrhotic portal hypertension.METHODS:Early cirrhotic portal hypertension was induced by bile duct ligation (BDL) for three weeks. One week after operation, sham-operated (SHAM) and BDL rats received rapamycin (2 mg/kg/day) by intraperitoneal injection for fourteen days. Vehicle-treated SHAM and BDL rats served as controls. Fibrosis, inflammation, and portal pressure were evaluated by histology, morphometry, and hemodynamics. Expressions of pro-fibrogenic and pro-inflammatory genes in liver were measured by RT-PCR; alpha smooth muscle actin (α-SMA) and antigen Ki67 were detected by immunohistochemistry; expressions of AKT/mTOR signaling molecules, extracellular-signal-regulated kinase 1/2 (ERK1/2), p-ERK1/2, and interleukin-1 beta (IL-1β) were assessed by western blot.RESULTS:The AKT/mTOR signaling pathway was markedly activated in the early phase of cirrhotic portal hypertension induced by BDL in rats. mTOR blockade by rapamycin profoundly improved liver function by limiting inflammation, fibrosis and portal pressure. Rapamycin significantly inhibited the expressions of phosphorylated 70KD ribosomal protein S6 kinase (p-P70S6K) and phosphorylated ribosomal protein S6 (p-S6) but not p-AKT Ser473 relative to their total proteins in BDL-Ra rats. Those results suggested that mTOR Complex 1 (mTORC1) rather than mTORC2 was inhibited by rapamycin. Interestingly, we also found that the level of p-ERK1/2 to ERK1/2 was significantly increased in BDL rats, which was little affected by rapamycin.CONCLUSIONS:The AKT/mTOR signaling pathway played an important role in the early phase of cirrhotic portal hypertension in rats, which could be a potential target for therapeutic intervention in the early phase of such pathophysiological progress.

Therapeutic Effect of Mtor Inhibitor Rapamycin in Early Phase Cirrhotic Portal Hypertension of Rats

Rapamycin Ameliorates Inflammation and Fibrosis in the Early Phase of Cirrhotic Portal Hypertension in Rats Through Inhibition of Mtorc1 but Not Mtorc2.

Rapamycin inhibits mesenteric neo-angiogenesis in portal hypertensive rats

Rapamycin prevents early steps of the development of diabetic nephropathy in rats.

Experimental study of activation of mtor/p70s6k signaling pathway in liver cirrhotic portal hypertension

Rapamycin Attenuates Splenomegaly in both Intrahepatic and Prehepatic Portal Hypertensive Rats by Blocking mTOR Signaling Pathway.

Beneficial Effect of Rapamycin on Liver Fibrosis in a Mouse Model (C57bl/6 Mouse)

Rapamycin Inhibits Epithelial-to-mesenchymal Transition of Peritoneal Mesothelium Cells Through Regulation of Rho GTPases.

Comparison of Anti-Peritoneal Fibrotic Effects Between an Mtorc1-Specific Blocker and a PI3K/mTOR Dual-Blocker.

Effects of Rapamycin on the Liver Regeneration after Partial Hepatectomy in Rats

Rapamycin Reverses Pulmonary Artery Smooth Muscle Cell Proliferation in Pulmonary Hypertension.

The Selective Mtorc1, Rather Than Dual Mtorc1/2, Inhibition Confers Liver Protection from Ischemia and Reperfusion Injury.

Experimental study on activation of mTOR signaling pathway promoting mesenteric angiogenesis in portal hyper-tensive rats

Effects of rapamycin on behavior,oxidative stress status and mitochondria-related gene expression in rat model of Parkinson′s disease

Effect of Rapamycin on Hepatic Metabolomics of Non-Alcoholic Fatty Liver Rats Based on Non-Targeted Platform

Rapamycin ameliorates CCl4-induced liver fibrosis in mice through reciprocal regulation of the Th17/Treg cell balance.

Antitumoral Activity of Rapamycin Mediated Through Inhibition of Hif-1alpha and Vegf in Hepatocellular Carcinoma

Protective Role of Rapamycin in Fibrotic Liver Ischemia/Reperfusion Injury (C57bl/6 Mouse)

Effects of Rapamycin on Nephropathy of Diabetic Rats and Expressions of Vascular Endothelial Growth Factor and Its Receptor

Effects of Rapamycin Pretreatment on Lung Injury Caused by Hepatic Cold Ischemia-Reperfusion Injury in Rats

Inhibition of Mtor Attenuates Store-Operated Ca2+ Entry in Cells from Endarterectomized Tissues of Patients with Chronic Thromboembolic Pulmonary Hypertension